4-(3-methylphenyl)-thiomorpholine 1,1-dioxide | 17741-61-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻嗪类
• 英文名称: 4-(3-methylphenyl)-thiomorpholine 1,1-dioxide
• 英文别名: N-(3-methylphenyl)thiomorpholine 1,1-dioxide；4-m-tolyl-thiomorpholine 1,1-dioxide；4-(m-Tolyl)-thiomorpholin-1,1-dioxid；4-(3-Methylphenyl)-1,4-thiazinane 1,1-dioxide
• CAS: 17741-61-6
• 化学式: C₁₁H₁₅NO₂S
• 分子量: 225.312
• InChiKey: HIGUQJQCISZUQT-UHFFFAOYSA-N

物化性质

• 熔点：
  99.5-103.3 °C
• 沸点：
  455.7±45.0 °C(predicted)
• 密度：
  1.220±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  二乙烯基砜 、 3-硝基甲苯 在 indium 、 溶剂黄146 作用下， 以 甲醇 为溶剂， 反应 24.0h， 以69%的产率得到4-(3-methylphenyl)-thiomorpholine 1,1-dioxide
  参考文献：
  名称：

  One-Pot Aryl-1,4-thiomorpholine 1,1-Dioxide Synthesis via Double 1,4-Addition of in situ Reduced Nitroarenes to Divinyl Sulfones

  摘要：

  One-pot reduction-triggered double aza-Michael type 1,4-addition reactions of various nitroarenes to divinyl sulfones were investigated. In the presence of indium/AcOH in MeOH or in sat. aq NH(4)Cl/MeOH, nitroarenes and divinyl sulfones were cyclized to give 1,4-thiomorpholine 1,1-dioxides.

  DOI：

  10.3987/com-09-11858

文献信息

• [EN] PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF<br/>[FR] INHIBITEURS DE LA PRMT5 CONTENANT UNE DIHYDRO- OU TÉTRAHYDRO-ISOQUINOLÉINE ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014100730A1

  公开（公告）日：2014-06-26

  Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5- mediated disorders are also described.

  本文描述了式（A）的化合物，其药学上可接受的盐以及药物组合物。本发明的化合物对抑制PRMT5活性是有用的。还描述了利用这些化合物治疗PRMT5介导的疾病的方法。
• [EN] PRMT5 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE PRMT5 ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014100734A1

  公开（公告）日：2014-06-26

  Described herein are compounds of formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

  本文描述了式（A）的化合物，其药学上可接受的盐以及药物组成物。本发明的化合物对抑制PRMT5活性是有用的。还描述了利用这些化合物治疗PRMT5介导的疾病的方法。
• [EN] ALKYNYL PHOSPHINE GOLD COMPLEXES FOR TREATING BACTERIAL INFECTIONS<br/>[FR] COMPLEXE ALCYNYLPHOSPHINE-OR POUR TRAITER LES INFECTIONS BACTÉRIENNES
  申请人：AUSPHERIX LTD

  公开号：WO2017093544A1

  公开（公告）日：2017-06-08

  A compound of formula (I) for use in the prevention or treatment of a bacterial infection.

  一种化合物，其化学式为（I），用于预防或治疗细菌感染。
• Boric Acid / Glycerol as an Efficient Catalyst for Synthesis of Thiomorpholine 1,1-Dioxide by Double Michael Addition Reaction in Water
  作者：Azim Ziyaei Halimehjnai、Seyedmorteza Hosseyni、Hadi Gholami、Mohammed M. Hashemi

  DOI：10.1080/00397911.2011.594930

  日期：2013.1

  Abstract Thiomorpholine 1,1-dioxides were prepared with double Michael addition reaction of aromatic amines to divinyl sulfone catalyzed by boric acid / glycerol in water. This catalyst system was also used for the Michael addition reaction of aromatic amines to electron-deficient alkenes. The reaction is simple and green and gives good to excellent yields. GRAPHICAL ABSTRACT

  摘要 以硼酸/甘油在水中催化芳香胺与二乙烯基砜的双迈克尔加成反应制备了硫代吗啉1,1-二氧化物。该催化剂体系也用于芳香胺与缺电子烯烃的迈克尔加成反应。该反应简单且绿色，产率高。图形概要
• RHO KINASE INHIBITORS
  申请人：Cook Brian Nicholas

  公开号：US20120165322A1

  公开（公告）日：2012-06-28

  The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式(I)的化合物和其药学上可接受的盐，其中R1和R2的定义如本文所述。本发明还涉及包含这些化合物的药物组合物、使用这些化合物治疗各种疾病和障碍的方法、制备这些化合物的过程以及在这些过程中有用的中间体。